These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23913213)

  • 1. RNA networks in ovarian cancer.
    Malek A
    Methods Mol Biol; 2013; 1049():111-7. PubMed ID: 23913213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA profiling in ovarian cancer.
    Iorio MV; Croce CM
    Methods Mol Biol; 2013; 1049():187-97. PubMed ID: 23913217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energy metabolism and changes in cellular composition in ovarian cancer.
    Malek A
    Methods Mol Biol; 2013; 1049():233-8. PubMed ID: 23913220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microarray-based transcriptome profiling of ovarian cancer cells.
    Cui J; Xu Y; Puett D
    Methods Mol Biol; 2013; 1049():119-37. PubMed ID: 23913214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
    Murphy SK; Huang Z; Wen Y; Spillman MA; Whitaker RS; Simel LR; Nichols TD; Marks JR; Berchuck A
    Mol Cancer Res; 2006 Apr; 4(4):283-92. PubMed ID: 16603642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach.
    Li L; Liu J; Yu W; Lou X; Huang B; Lin B
    Methods Mol Biol; 2013; 1049():139-69. PubMed ID: 23913215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation.
    Silva JM; Boczek NJ; Berres MW; Ma X; Smith DI
    RNA Biol; 2011; 8(3):496-505. PubMed ID: 21532345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
    Reimer D; Sadr S; Wiedemair A; Goebel G; Concin N; Hofstetter G; Marth C; Zeimet AG
    Ann N Y Acad Sci; 2006 Dec; 1091():270-81. PubMed ID: 17341621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinately up-regulated genes in ovarian cancer.
    Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
    Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of candidate methylation-responsive genes in ovarian cancer.
    Menendez L; Walker D; Matyunina LV; Dickerson EB; Bowen NJ; Polavarapu N; Benigno BB; McDonald JF
    Mol Cancer; 2007 Jan; 6():10. PubMed ID: 17254359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.
    Kurita T; Izumi H; Kagami S; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Kohno K
    Cancer Sci; 2012 Feb; 103(2):239-444. PubMed ID: 22098591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma.
    Dammann RH; Kirsch S; Schagdarsurengin U; Dansranjavin T; Gradhand E; Schmitt WD; Hauptmann S
    Int J Oncol; 2010 Jan; 36(1):171-9. PubMed ID: 19956846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-coding RNAs and cancer: new paradigms in oncology.
    Lee SK; Calin GA
    Discov Med; 2011 Mar; 11(58):245-54. PubMed ID: 21447283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Main principles and outcomes of DNA methylation analysis.
    Murphy SK; Bassil CF; Huang Z
    Methods Mol Biol; 2013; 1049():67-74. PubMed ID: 23913209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signature of a silent killer: expression profiling in epithelial ovarian cancer.
    Le Page C; Provencher D; Maugard CM; Ouellet V; Mes-Masson AM
    Expert Rev Mol Diagn; 2004 Mar; 4(2):157-67. PubMed ID: 14995903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of dicer expression in ovarian cancer tissues.
    Pampalakis G; Diamandis EP; Katsaros D; Sotiropoulou G
    Clin Biochem; 2010 Feb; 43(3):324-7. PubMed ID: 19782670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of protein-coding and intronic noncoding RNAs down-regulated in clear cell renal carcinoma.
    Brito GC; Fachel AA; Vettore AL; Vignal GM; Gimba ER; Campos FS; Barcinski MA; Verjovski-Almeida S; Reis EM
    Mol Carcinog; 2008 Oct; 47(10):757-67. PubMed ID: 18348187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.